Global Perspectives: Current and Future Management of Breast Cancer 2023
Expert perspectives and strategic insights on the latest therapeutic developments in breast cancer
FACULTY CO-CHAIR
Nadia Harbeck, MD, PhD
Ludwig-Maximilian University of Munich, Germany
FACULTY CO-CHAIR
Joyce A. O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA
Faculty Members
Mark Pegram, MD
Stanford University School of Medicine, CA, USA
Melinda L. Telli, MD
Stanford University School of Medicine, CA, USA
Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Reshma L. Mahtani, DO
Miami Cancer Institute, Baptist Health South Florida, USA
Peter Schmid, MD, PhD
St Bartholomew’s Hospital, London, UK
Joseph Gligorov, MD, PhD
Tenon Hospital (AP-HP), Paris, France
Valentina Guarneri, MD, PhD
University of Padua, Italy
Javier Cortés, MD, PhD
International Breast Cancer Center, Barcelona, Spain
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Current and Emerging Biomarkers and Testing Methodologies in BC
- Therapeutic Horizons in HR+ Advanced BC
- Clinical Implications of HER2-Low BC
- Maximizing Potential Targeting of HER2 in HER2+ mBC
- Therapeutic Horizons in HR+ Early BC
- The Changing Landscape of HER2+ Early BC
- Standard and Emerging Strategies for High-Risk, Early-Stage TNBC
- Current and Investigational Approaches in Metastatic TNBC
